Filter posts

CMS’s Own Data Do NOT Support Claims on Part B Drug Spending

In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for …

In Speaker Pelosi’s Extreme Drug Pricing Bill, Funding for NIH is MIA

Supporters of Speaker Pelosi’s extreme drug pricing bill (H.R. 3) want us to believe that …

#BIOSummit19 Concludes with Message of Hope Offered by Innovation

Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health …

#BIOSummit19: Education and Partnerships Raise Awareness

When Mark Dant’s son Ryan was first diagnosed with MPS-I, a rare genetic disorder that …

Greenwood: Solving the Looming Superbug Crisis Will Require Bold Action From Congress

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and …

Fundraising Companies Find Strategic Partners that Best Fit Their Stage of Development at BIO Invest...

Since its inception 17 years ago, the BIO Investor Forum has become the premier event …

IPOs Are a Gateway to More Diverse Biotech Boards

As more biotechnology executives begin to focus on strategies to diversify their boards to avoid …

Investment Crackdown Prompts Chinese Investors to Leave U.S. Biotech Market and Focus on Europe

Confusion among Chinese investors about shifting U.S. regulatory policy is draining billions of dollars from …

Gene Therapies: The Pipeline Towards a New Era for Patients

On Tuesday morning at the BIO Investor Forum, leaders from top companies at the forefront of …

BIO Mourns Passing of Dr. John Holaday

On behalf of the team at BIO, we send our deepest condolences to the family …